Recombinant Human NCAM-1/CD56 Fc Chimera Protein, CF Summary
Accession # P13591-1
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 500 μg/mL in PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Immobilized Recombinant Human NCAM‑1/CD56 Fc Chimera (Catalog # 10136-NC) supports the adhesion of Neuro‑2A mouse neuroblastoma cells. The ED50for this effect is 1-6 μg/mL.
2 μg/lane of Recombinant Human NCAM-1/CD56 Fc Chimera (Catalog # 10136-NC) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® blue staining, showing single bands at 115-135 kDa and 230-270 kDa, respectively.
Neural cell adhesion molecule 1 (NCAM-1), also known as CD56, is a multifunctional member of the Ig superfamily. It belongs to a family of membrane-bound glycoproteins that are involved in Ca++ independent cell matrix and homophilic or heterophilic cell-cell interactions. There are three main forms of human NCAM-1 that arise by alternate splicing. These are designated NCAM-120/NCAM-1 761 amino acid (aa), NCAM-140 (848 aa), and NCAM-180 (1120 aa). NCAM-120 is GPI-linked, while NCAM-140 and NCAM-180 are type I transmembrane glycoproteins (1-3). Additional alternate splicing adds considerable diversity to all three forms, and extracellular proteolytic processing is possible for NCAM-180 (4, 5). Human NCAM-1 is synthesized as a 761 aa preproprecursor, containing a signal sequence, a large GPI-linked extracellular domain (ECD), and a short C-terminal prosegment (1). The mature ECD contains five C-2 type Ig-like domains and two fibronectin type III domains. The mature human ECD shares 93% and 95% aa sequence identity with the mouse and rat NCAM-1 ECD, respectively. NCAM-1 appears to be highly sialylated. The polysialyation of NCAM-1 reduces its adhesive property and increases its neurite outgrowth promoting features (6). NCAM-1 in the adult brain shows a decline of sialylation relative to earlier developmental periods. In regions that retain a high degree of neuronal plasticity, however, the adult brain continues to express polysialylated-NCAM-1, suggesting sialylation of NCAM-1 is involved in regenerative processes and synaptic plasticity (7-10). NCAM can function as a receptor for GDNF family of ligands. GDNF stimulates Schwann cell migration and neurite outgrowth in hippocampal and cortical neurons through binding to NCAM-1 and activation of Fyn, independently of RET (11). NCAM-1 also interacts with Ig IIIC isoform of the FGFR1 and plays an important role in developmental events as well as tumor progression (12). It promotes ovarian cancer progression through FGF R1 interaction and stimulates dissemination of tumor to organs of peritoneal cavity (13). NCAM-1 is preferentially expressed in NK cells and a subset of T lymphocytes that mediate MHC-unrestricted cell-mediated cytotoxicity (14). High expression of CD56/NCAM-1 differentiates NK cells as having an activated phenotype. CD56(+high) NK cells mediate heightened effector functions (proliferation, IFN-gamma and IL-10 but not IL-13 production) in response to IL-12 (15). NCAM-1 functions as pathogen recognition receptor during an innate immune response (16). CD56+ T cells can inhibit HIV infection of macrophages (17). Due to expression on immune cells NCAM-1 has great implications on tumor progression, infection, and disease development.
- Dickson, G. et al. (1987) Cell 50:1119.
- Lanier, L.L. et al. (1991) J. Immunol. 146:4421.
- Hemperly, J.J. et al. (1990) J. Mol. Neurosci. 2:71.
- Rutishauser, U.and C. Goridis (1986) Trends Genet. 2:72.
- Vawter, M.P. et al. (2001) Exp. Neurol. 172:29.
- Rutihauser, U. (1990) Adv. Exp. Med. Biol. 265:179.
- Becker, C.G. et al. (1996) J. Neurosci. Res. 45:143.
- Doherty, P. et al. (1995) J. Neurobiol. 26:437.
- Eckardt, M. et al. (2000) J. Neurosci. 20:5234.
- Muller, D. et al. (1996) Neuron 17:413.
- Paratcha, G. et al. (2003) Cell. 113:867.
- Sanchez-Heras, E. et al. (2006) J Biol Chem. 281:35208.
- Zecchini, S. et al. (2011) EMBO Mol Med. 3:480.
- Lanier, L.L. et al. (1991) J Immunol. 146:4421.
- Loza, M.J. et al. (2004) J Immunol. 172:88.
- Ziegler, S. et al. (2017) Sci Rep. 7:6138.
- Hou, W. et al. (2012) J Leukoc Biol. 92:343.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human NCAM-1/CD56 Fc Chimera Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human NCAM-1/CD56 Fc Chimera Protein, CF and earn rewards!
Have you used Recombinant Human NCAM-1/CD56 Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image